Report on the Lipid Research Clinic trials

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Pharmacology

Background:

• Hypercholesterolemia is a major risk factor for coronary heart disease (CHD).
• Primary prevention trials are crucial for evaluating interventions in asymptomatic individuals.
• Bile acid sequestrants represent a class of lipid-lowering drugs.

Purpose of the Study:

• To evaluate the efficacy of cholestyramine in preventing primary coronary events in hypercholesterolemic men.
• To assess the impact of cholestyramine on CHD mortality and non-fatal myocardial infarction.
• To investigate the relationship between lipid level reduction and cardiovascular risk reduction.

Main Methods:

• Randomized, double-blind, placebo-controlled trial involving 3806 asymptomatic hypercholesterolemic men (age 35-59).
• Treatment group received cholestyramine and a low-fat, low-cholesterol diet; control group received placebo and diet.
• Follow-up for a minimum of seven years to monitor primary endpoints and other cardiovascular events.

Main Results:

• Cholestyramine treatment achieved an 8% reduction in total cholesterol and 12% in LDL cholesterol compared to placebo.
• A 19% reduction in the risk of definite CHD death or non-fatal myocardial infarction was observed (P>0.05).
• Significant reductions were noted in positive exercise tests (25%), angina (20%), and coronary bypass surgery (21%).

Conclusions:

• Cholestyramine therapy is effective in reducing the risk of primary coronary events in hypercholesterolemic men.
• Risk reduction is directly proportional to the achieved reduction in total and LDL cholesterol levels.
• Cholestyramine also demonstrated a benefit in delaying atherosclerotic lesion progression in a secondary prevention trial.